Slide 1: 2Q23 Earnings Presentation
2Q23 Earnings Presentation July 28, 2023
Slide 2: Disclaimer
Disclaimer Forward-looking statements are exclusively related to the prospects of the business, its operating and financial results, and prospects for growth. These data are merely projections and, as such, based exclusively on our management's expectations for the future of the business and its con
Slide 3: 8.6% of sell-out growth in 2Q23
8.6%' of sell-out growth in 2Q23 SELL-OUT COMPOUNDED ANNUAL GROWTH 2Q21 vs. 2Q23 > +17.0% (0.4 percentagem point above the market?) 8.6% 26.0% 2Q21 2Q22 2Q23 3 Noto: ‘Sellout PPP (Pharmacy Purchase Price), as infomred by IQVIA; 2As informed by IQVIA - | ) Hypera pharma
Slide 4: 2023 Highlights
2023 Highlights OQ 2Q23 main launches fila tla = i o/1 Al Non-Retail Market growth of 54.9% Qe Interest on Equity of R$194.8 million (R$O.31/share) in 2Q23 Note: ‘Does not consider the non-recurring sale of immunoglobulin — «(| ) Hypera
Slide 5: New composition of the Board of Directors
New composition of the Board of Directors L Alvaro Stainfeld (Chairman) Bernardo Malpica Esteban Malpica Hugo Leal Luciana de Queiroz Dr. Flair Carrilho Maria Carolina Lacerda Eliana Helena Chimenti Mauro Cunha Accountant and MBA from Stanford University's Graduate School of Business, worked in Inve
Slide 6: 2023 Highlights
2023 Highlights 2022 Integrated Annual Report GREAT mem GCPTW New Certification WORK’ Difiheiro 6 brands in IstoE Dinheiro's most valuable brands ranking WO S vpera
Slide 7: 2023 Results (R$ million)
2023 Results (R$ million) NET REVENUE > R$2,231.1 417.7%! GROSS MARGIN 63.2%? -50bps! MARKETING EXPENSES 15.9%? -60bps! SELLING EXPENSES 11.0%? +100bps! GENERAL AND ADMINISTRATIVE EXPENSES 4.0%? +30bps'! EBITDA MARGIN FROM CONTINUING OP. (excl. OTHERS) 34.6%? -100bps! NET INCOME FROM CONTINUING OPER
Slide 8: Gross cash flow and net debt bridge
1Q23 Gross Cash Flow from PP&E Intangibles Free Cash Flow Financing Cash IOC 2Q23 Gross 2Q23 Gross 2Q23 Net Debt Cash Operations 2Q23 Flow Cash Debt
Slide 9: Slide 9